Quick Answer
Aclaris Therapeutics, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $7.83 million for the year ending 2025.
- Aclaris Therapeutics, Inc. showed a decrease of -58.2% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Aclaris Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 9 years of available data (2017 to 2025), Aclaris Therapeutics, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 365.0%.
- Historical annual values: Fiscal year 2025: $7.83 million | Fiscal year 2024: $18.72 million | Fiscal year 2023: $31.25 million | Fiscal year 2022: $29.75 million | Fiscal year 2021: $6.76 million | Fiscal year 2020: $6.48 million | Fiscal year 2019: $4.23 million | Fiscal year 2018: $6.15 million | Fiscal year 2017: $1.68 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: